Loading...

MeiraGTx Holdings

Nasdaq:MGTX
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MGTX
Nasdaq
$812M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The last earnings update was 11 days ago. More info.


Add to Portfolio Compare Print
  • MeiraGTx Holdings has significant price volatility in the past 3 months.
MGTX Share Price and Events
7 Day Returns
3.7%
NasdaqGS:MGTX
-0.3%
US Biotechs
-2.1%
US Market
1 Year Returns
-
NasdaqGS:MGTX
-5%
US Biotechs
1.3%
US Market
MGTX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MeiraGTx Holdings (MGTX) 3.7% 31.6% 90.8% - - -
US Biotechs -0.3% -2.5% -5.2% -5% 4.2% 10.1%
US Market -2.1% -4.2% 0% 1.3% 33.5% 38%
1 Year Return vs Industry and Market
  • No trading data on MGTX.
  • No trading data on MGTX.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is MeiraGTx Holdings undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of MeiraGTx Holdings to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for MeiraGTx Holdings.

NasdaqGS:MGTX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.2%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:MGTX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.38
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.379 (1 + (1- 21%) (0.44%))
1.257
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.26
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.257 * 5.96%)
10.22%

Discounted Cash Flow Calculation for NasdaqGS:MGTX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for MeiraGTx Holdings is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:MGTX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.22%)
2019 46.02 Est @ 13.15% 41.75
2020 50.64 Est @ 10.02% 41.68
2021 54.60 Est @ 7.84% 40.78
2022 58.05 Est @ 6.3% 39.33
2023 61.08 Est @ 5.23% 37.55
2024 63.82 Est @ 4.48% 35.59
2025 66.35 Est @ 3.96% 33.57
2026 68.73 Est @ 3.59% 31.55
2027 71.02 Est @ 3.33% 29.57
2028 73.25 Est @ 3.15% 27.68
Present value of next 10 years cash flows $359.03
NasdaqGS:MGTX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $73.25 × (1 + 2.73%) ÷ (10.22% – 2.73%)
$1,004.27
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,004.27 ÷ (1 + 10.22%)10
$379.41
NasdaqGS:MGTX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $359.03 + $379.41
$738.44
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $738.44 / 33.34
$22.15
NasdaqGS:MGTX Discount to Share Price
Calculation Result
Value per share (USD) From above. $22.15
Current discount Discount to share price of $24.35
= -1 x ($24.35 - $22.15) / $22.15
-9.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of MeiraGTx Holdings is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MeiraGTx Holdings's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MeiraGTx Holdings's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:MGTX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-3.58
NasdaqGS:MGTX Share Price ** NasdaqGS (2019-05-24) in USD $24.35
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 17.95x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MeiraGTx Holdings.

NasdaqGS:MGTX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:MGTX Share Price ÷ EPS (both in USD)

= 24.35 ÷ -3.58

-6.8x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MeiraGTx Holdings is loss making, we can't compare its value to the US Biotechs industry average.
  • MeiraGTx Holdings is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does MeiraGTx Holdings's expected growth come at a high price?
Raw Data
NasdaqGS:MGTX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.8x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
-18.5%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.19x
United States of America Market PEG Ratio Median Figure of 2,120 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MeiraGTx Holdings, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MeiraGTx Holdings's assets?
Raw Data
NasdaqGS:MGTX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $4.33
NasdaqGS:MGTX Share Price * NasdaqGS (2019-05-24) in USD $24.35
United States of America Biotechs Industry PB Ratio Median Figure of 418 Publicly-Listed Biotechs Companies 3.19x
United States of America Market PB Ratio Median Figure of 5,207 Publicly-Listed Companies 1.8x
NasdaqGS:MGTX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:MGTX Share Price ÷ Book Value per Share (both in USD)

= 24.35 ÷ 4.33

5.62x

* Primary Listing of MeiraGTx Holdings.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MeiraGTx Holdings is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess MeiraGTx Holdings's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. MeiraGTx Holdings has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is MeiraGTx Holdings expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-18.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MeiraGTx Holdings expected to grow at an attractive rate?
  • Unable to compare MeiraGTx Holdings's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare MeiraGTx Holdings's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • MeiraGTx Holdings's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:MGTX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:MGTX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts -18.5%
NasdaqGS:MGTX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 67.3%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.4%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:MGTX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:MGTX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 4 -120 1
2019-12-31 4 -105 1
NasdaqGS:MGTX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 1 41 -86
2018-12-31 -59 -85
2018-09-30 -51 -73
2018-06-30 -44 -66
2018-03-31 -29 -42
2017-12-31 -18 -32
2016-12-31 -14 -20

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • MeiraGTx Holdings is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • MeiraGTx Holdings's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:MGTX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from MeiraGTx Holdings Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:MGTX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -3.45 -3.45 -3.45 1.00
2019-12-31 -3.12 -3.12 -3.12 1.00
NasdaqGS:MGTX Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -3.58
2018-12-31 -4.47
2018-09-30 -5.04
2018-06-30 -6.64
2018-03-31 -4.84
2017-12-31 -3.72
2016-12-31 -2.44

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MeiraGTx Holdings will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess MeiraGTx Holdings's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MeiraGTx Holdings has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has MeiraGTx Holdings performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MeiraGTx Holdings's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MeiraGTx Holdings does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare MeiraGTx Holdings's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MeiraGTx Holdings's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
MeiraGTx Holdings's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MeiraGTx Holdings Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:MGTX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 0.78 -85.59 41.86 39.67
2018-12-31 -84.67 44.48 33.62
2018-09-30 -72.78 37.71 28.61
2018-06-30 -65.99 33.45 26.89
2018-03-31 -42.08 18.30 24.46
2017-12-31 -31.85 9.33 22.36
2016-12-31 -19.57 6.03 14.04

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MeiraGTx Holdings has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if MeiraGTx Holdings has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MeiraGTx Holdings improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MeiraGTx Holdings's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MeiraGTx Holdings has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is MeiraGTx Holdings's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MeiraGTx Holdings's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MeiraGTx Holdings is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MeiraGTx Holdings's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of MeiraGTx Holdings's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 64.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MeiraGTx Holdings Company Filings, last reported 1 month ago.

NasdaqGS:MGTX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 144.42 3.59 227.28
2018-12-31 81.06 0.03 68.08
2018-09-30 96.34 0.04 88.56
2018-06-30 108.47 0.05 102.06
2018-03-31 36.44 0.06 32.36
2017-12-31 3.97 1.51 8.55
2016-12-31 15.69 0.01 17.48
  • MeiraGTx Holdings's level of debt (2.5%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if MeiraGTx Holdings's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Whilst loss making MeiraGTx Holdings has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.
  • Whilst loss making MeiraGTx Holdings has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 1.6% per year.
X
Financial health checks
We assess MeiraGTx Holdings's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MeiraGTx Holdings has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is MeiraGTx Holdings's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MeiraGTx Holdings dividends. Estimated to be 0% next year.
If you bought $2,000 of MeiraGTx Holdings shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MeiraGTx Holdings's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MeiraGTx Holdings's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:MGTX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:MGTX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MeiraGTx Holdings has not reported any payouts.
  • Unable to verify if MeiraGTx Holdings's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MeiraGTx Holdings's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MeiraGTx Holdings has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of MeiraGTx Holdings's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess MeiraGTx Holdings's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MeiraGTx Holdings afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MeiraGTx Holdings has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of MeiraGTx Holdings's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Alexandria Forbes
COMPENSATION $22,998,522
AGE 53
TENURE AS CEO 4.2 years
CEO Bio

Dr. Alexandria Forbes, Ph.D. serves as the Chief Executive Officer and President at MeiraGTx Limited since 2015. Prior to joining MeiraGTx, Dr. Forbes served as Senior Vice President of Strategic Operations and Chief Commercial Officer at Kadmon from 2013 to 2015 and served as its Director until May 25, 2018. She served as Managing Director of Sivik Global Healthcare, LLC. Dr. Forbes spent 10 years as a healthcare investor at Sivik/Argus Partners. At Sivik Partners Dr. Forbes was responsible for investments in biotechnology, specialty pharmaceuticals and diagnostics, and was portfolio manager for the Sivik Global Life Science Fund, a long-biased public markets fund investing in biotechnology companies globally. She serves as Director of MeiraGTx Limited. Before entering the hedge fund industry, Dr. Forbes was a Human Frontiers/Howard Hughes postdoctoral fellow at the Skirball Institute of Biomolecular Medicine at NYU Langone Medical Center, where her research focused on cytoplasmic determinants and cell signaling pathways involved in the migration, establishment and maintenance of germ line stem cells in Drosophila melanogaster. Prior to this, Dr. Forbes was a research fellow at Duke University, and also at the Carnegie Institute at Johns Hopkins University where she studied the role of the hedgehog gene and it’s signaling pathway in the Drosophila embryo and adult. Dr. Forbes received her Ph.D. in Molecular Genetics from Oxford University, UK and her M.A. in Natural Sciences from Cambridge University, UK.

CEO Compensation
  • Alexandria's compensation has increased whilst company is loss making.
  • Alexandria's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the MeiraGTx Holdings management team in years:

0.3
Average Tenure
53
Average Age
  • The average tenure for the MeiraGTx Holdings management team is less than 2 years, this suggests a new team.
Management Team

Alexandria Forbes

TITLE
CEO, President & Director
COMPENSATION
$23M
AGE
53
TENURE
4.2 yrs

Richard Giroux

TITLE
COO & CFO
COMPENSATION
$22M
AGE
45
TENURE
0.1 yrs

Stuart Naylor

TITLE
Chief Development Officer
COMPENSATION
$2M
AGE
55
TENURE
4.1 yrs

Elizabeth Broder

TITLE
Associate Vice President of Investor Relations
TENURE
0.3 yrs

Bruce Gottlieb

TITLE
General Counsel & Secretary
AGE
42
TENURE
0.1 yrs

Micah Zajic

TITLE
Vice President of Corporate Development

Greg Petsko

TITLE
Chief Scientist & Chairman of Scientific Advisory Board

Robin Ali

TITLE
Head of Preclinical Ophthalmology & Member of Scientific Advisory Board

James Christie

TITLE
Senior Vice President of Manufacturing & Supply Chain
AGE
60

Ian Delmage

TITLE
Head of Quality
Board of Directors Tenure

Average tenure and age of the MeiraGTx Holdings board of directors in years:

3.9
Average Tenure
67.5
Average Age
  • The tenure for the MeiraGTx Holdings board of directors is about average.
Board of Directors

Keith Harris

TITLE
Chairman of the Board
COMPENSATION
$156K
AGE
65
TENURE
1.3 yrs

Alexandria Forbes

TITLE
CEO, President & Director
COMPENSATION
$23M
AGE
53
TENURE
4.2 yrs

Greg Petsko

TITLE
Chief Scientist & Chairman of Scientific Advisory Board

Robin Ali

TITLE
Head of Preclinical Ophthalmology & Member of Scientific Advisory Board

Joel Marcus

TITLE
Director
COMPENSATION
$97K
AGE
70
TENURE
3.9 yrs

Tom Shenk

TITLE
Member of Scientific Advisory Board & Director
COMPENSATION
$118K
AGE
71
TENURE
3.9 yrs

Arnie Levine

TITLE
Member of Scientific Advisory Board & Director
COMPENSATION
$88K
AGE
78

Neil Mendoza

TITLE
Director
COMPENSATION
$94K
AGE
58
TENURE
3.9 yrs

Scott Small

TITLE
Member of Scientific Advisory Board

Michael Kaplitt

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
05. Mar 19 Buy Perceptive Advisors LLC Company 01. Mar 19 01. Mar 19 1,304,348 $13.80 $18,000,002
12. Jun 18 Buy Perceptive Advisors LLC Company 08. Jun 18 12. Jun 18 1,383,333 $15.22 $20,760,995
X
Management checks
We assess MeiraGTx Holdings's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MeiraGTx Holdings has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Do Directors Own MeiraGTx Holdings plc (NASDAQ:MGTX) Shares?

The big shareholder groups in MeiraGTx Holdings plc (NASDAQ:MGTX) have power over the company. … With a market capitalization of US$365m, MeiraGTx Holdings is a small cap stock, so it might not be well known by many institutional investors. … See our latest analysis for MeiraGTx Holdings

Simply Wall St -

What Does MeiraGTx Holdings plc's (NASDAQ:MGTX) Ownership Structure Look Like?

In this article, I will take a quick look at MeiraGTx Holdings plc’s (NASDAQ:MGTX) recent ownership structure – an unconventional investing subject, but an important one. … The impact of a company's ownership structure affects both its short- and long-term performance. … Therefore, it is beneficial for us to examine MGTX's ownership structure in more detail.

Simply Wall St -

Company Info

Description

MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson’s diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson’s program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren’s syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company’s proprietary riboswitch technology. The company was founded in 2015 and is headquartered in New York, New York.

Details
Name: MeiraGTx Holdings plc
MGTX
Exchange: NasdaqGS
Founded: 2015
$811,891,482
33,342,566
Website: http://www.meiragtx.com
Address: MeiraGTx Holdings plc
430 East 29th Street,
10th Floor,
New York,
New York, 10016,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS MGTX Ordinary Shares Nasdaq Global Select US USD 08. Jun 2018
Number of employees
Current staff
Staff numbers
74
MeiraGTx Holdings employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/25 00:59
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/05/17
Last earnings filing: 2019/05/14
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.